N. Ahmed, V. S. Brawley, M. Hegde, C. Robertson, A. Ghazi et al., , 2015.

, Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptormodified T cells for the immunotherapy of HER2-positive sarcoma, J Clin Oncol, vol.33, issue.15, pp.1688-96

N. Ahmed, V. S. Salsman, E. Yvon, C. U. Louis, L. Perlaky et al., Immunotherapy for osteosarcoma : genetic modification of T cells overcomes low levels of tumor antigen expression, Mol Ther, vol.17, issue.10, pp.1779-87, 2009.

P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi et al., , 2005.

, Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production, Cancer Res, vol.65, issue.7, pp.2964-2971

M. D. Anderson, R. De-borja, M. D. Young, F. Fuligni, A. Rosic et al., Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors, Science, vol.361, issue.6405, 2018.

K. Ando, M. Mori, N. Corradini, F. Redini, and D. Heymann, Mifamurtide for the treatment of nonmetastatic osteosarcoma, Expert Opin. Pharmacother, vol.12, pp.285-292, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00667530

A. Borowski, U. Dirksen, L. Lixin, R. L. Shi, U. Göbel et al., Structure and function of ETAA16: a novel cell surface antigen in Ewing's tumours, Cancer Immunol Immunother, vol.55, issue.4, pp.363-374, 2006.

C. Brard, S. Piperno-neumann, J. Delaye, L. Brugières, L. V. Hampson et al.,

, Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma, BMJ Open, vol.9, issue.5, p.25877

B. J. Biller, A. Guth, J. H. Burton, and S. W. Dow, Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma, J Vet Intern. Med, vol.24, pp.1118-1123, 2010.

E. M. Bluman, P. G. Coulie, S. Xiaojuan, J. Machan, C. Lin et al., Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules, J Orthop Res, vol.25, pp.678-684, 2007.

U. Brinkmann, G. Vasmatzis, B. Lee, and I. Pastan, Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database, Cancer Res, vol.59, issue.7, pp.1445-1448, 1999.

H. K. Brown, K. Schiavone, F. Gouin, M. F. Heymann, and D. Heymann, Biology of bone sarcomas and new therapeutic developments, Calcif Tissue Int, vol.20102, issue.2, pp.174-195, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01653600

H. K. Brown, M. Tellez-gabriel, P. F. Cartron, F. M. Vallette, M. F. Heymann et al., Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?, Drug Discov Today, vol.24, issue.3, pp.763-772, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-01947472

E. P. Buddingh, M. L. Kuijjer, R. A. Duim, H. Bürger, K. Agelopoulos et al., Tumor-infiltrating macrophages are associated with metastasis suppression in highgrade osteosarcoma: a rationale for treatment with macrophage activating agents, Clin Cancer Res, vol.17, pp.2110-2119, 2011.

F. M. Burnet, The concept of immunological surveillance, Prog Exp Tumor Res, vol.13, pp.1-27, 1970.

M. Césaire, J. Thariat, S. M. Candéias, D. Stefan, Y. Saintigny et al., , 2018.

, Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?, Int J Mol Sci, vol.19, issue.12

T. C. Chang, R. A. Carter, Y. Li, Y. Li, H. Wang et al., The neoepitope landscape in pediatric cancers, Genome Med, vol.9, issue.1, p.78, 2017.

A. J. Chou, E. S. Kleinerman, and M. D. Krailo, Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group, Cancer, vol.115, pp.5339-5387, 2009.

T. P. Cripe, M. C. Ngo, J. I. Geller, C. U. Louis, M. A. Currier et al., , 2015.

, Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients, Mol Ther, vol.23, issue.3, pp.602-608

B. D. Crompton, C. Stewart, A. Taylor-weiner, G. Alexe, and K. Kurek, The genomic landscape of pediatric Ewing sarcoma, Cancer Discov, vol.4, issue.11, pp.1326-1341, 2014.

S. P. D'angelo, L. Melchiori, M. S. Merchant, D. Bernstein, J. Glod et al., Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259 T cells in synovial sarcoma, Cancer Discov, vol.8, issue.8, pp.944-957, 2018.

P. D'arcy, W. Maruwge, B. Wolahan, L. Ma, and B. Brodin, Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells, PLoS One, vol.9, issue.4, p.95136, 2014.

N. L. Denton, C. Y. Chen, B. Hutzen, M. A. Currier, T. Scott et al., , 2018.

, Myelolytic treatments enhance oncolytic herpes virotherapy in models of Ewing sarcoma by modulating the immune microenvironment, Mol Ther Oncolytics, vol.11, pp.62-74

C. Derenzo and S. Gottschalk, Genetically modified T-cell therapy for the treatment of osteosarcoma: an update, J Clin Cell Immunol, vol.7, issue.2, 2016.

Q. Dong and X. Ma, B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma, Biomed Res Int, p.156432, 2015.

P. Dhupkar, N. Gordon, J. Stewart, and E. S. Kleinerman, Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases, Cancer Med, vol.7, issue.6, pp.2654-2664, 2018.

C. Dumars, J. M. Ngyuen, A. Gaultier, R. Lanel, N. Corradini et al., Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, issue.48, pp.78343-78354, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466103

G. P. Dunn, L. J. Old, and R. D. Schreiber, The three Es of cancer immunoediting, Annu Rev Immunol, vol.22, pp.329-60, 2004.

L. Endo-munoz, A. Evdokiou, and N. A. Saunders, The role of osteoclasts and tumourassociated macrophages in osteosarcoma metastasis, Biochim Biophys Acta, vol.1826, issue.2, pp.434-476, 2012.

X. Fang, C. Jiang, and Q. Xia, Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response, Genet Mol Res, vol.14, issue.4, pp.11763-70, 2015.

L. Fernández, J. Y. Metais, A. Escudero, M. Vela, J. Valentín et al., , 2017.

, Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells, Clin Cancer Res, vol.23, pp.5824-5835

L. Fernández, J. Valentín, M. Zalacain, W. Leung, A. Patiño-garcía et al., Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner, Cancer Lett, vol.368, issue.1, pp.54-63, 2015.

F. Fiore, B. Castella, B. Nuschak, R. Bertieri, S. Mariani et al., Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid, Blood, vol.110, issue.3, pp.921-927, 2007.

C. Fleming, S. Morissey, Y. Cai, and . Yan, ?? T Cells: Unexpected Regulators of Cancer Development and Progression, Trends Cancer, vol.3, issue.8, pp.561-570, 2017.

J. L. Foell, M. Hesse, I. Volkmer, B. J. Schmiedel, I. Neumann et al., , 2008.

, Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen, Pediatr Blood Cancer, vol.51, issue.2, pp.228-234

E. D. Foucher, S. Blanchard, L. Preisser, E. Garo, N. Ifrah et al., IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFN?, PLoS One, vol.8, issue.2, p.56045, 2013.

B. Fritzsching, J. Fellenberg, L. Moskovszky, Z. Sápi, T. Krenacs et al.,

, CD8 + /FOXP3 + ratio in osteosarcoma microenvironment separates survivors from nonsurvivors: a multicentre validated retrospective study. Oncoimmunology 4; e990800

M. Garcia-moure, N. Martinez-vélez, A. Patiño-garcía, and M. M. Alonso, Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope, J Bone Oncol, vol.9, pp.41-47, 2016.

G. Germano, R. Frapolli, M. Simone, M. Tavecchio, E. Erba et al., , 2010.

, Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells, Cancer Res, vol.70, issue.6, pp.2235-2279

G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce et al., Role of macrophage targeting in the antitumor activity of trabectedin, Cancer Cell, vol.23, issue.2, pp.249-62, 2013.

G. Grignani, L. D'ambrosio, and . Y. Pignochino, Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group, Lancet Oncol, vol.19, issue.10, pp.30438-30446, 2018.

Y. Guan, R. Zhang, Z. Peng, D. Dong, G. Wei et al., Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer, J Bone Oncol, vol.9, pp.59-64, 2017.

S. R. Guma, D. A. Lee, Y. Ling, N. Gordon, and E. S. Kleinerman, Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis, Pediatr Blood Cancer, vol.61, issue.8, pp.1362-1370, 2014.

Q. Han, H. Shi, and F. Liu, CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma, Int Immunopharmacol, vol.34, pp.101-106, 2016.

X. He, H. Lin, L. Yuan, and B. Li, Combination therapy with L-arginine and ?-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice, Cancer Biol Ther, vol.18, issue.2, pp.94-100, 2017.

Y. T. He, Q. M. Zhang, Q. C. Kou, and B. Tang, In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma, Oncol Lett, vol.12, issue.2, pp.1101-1106, 2016.

P. Koirala, M. E. Roth, J. Gill, S. Piperdi, J. M. Chinai et al., Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma, Sci Rep, vol.6, p.30093, 2016.

M. Kostine, A. H. Cleven, N. F. De-miranda, A. Italiano, A. M. Cleton-jansen et al., Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype, Mod Pathol, vol.29, issue.9, pp.1028-1065, 2016.

D. K. Krishnadas, S. Shusterman, F. Bai, L. Diller, J. E. Sullivan et al., A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma, Cancer Immunol Immunother, vol.64, issue.10, pp.1251-60, 2015.

A. Kuldkepp, M. Karakai, E. Toomsoo, O. Reinsalu, and R. Kurg, Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells, Oncotarget, vol.10, issue.38, pp.3694-3708, 2019.

J. P. Lai, P. F. Robbins, M. Raffeld, P. P. Aung, M. Tsokos et al., , 2012.

, NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis, Mod Pathol, vol.25, issue.6, pp.854-858

A. Le-cesne, P. Marec-berard, J. Y. Blay, N. Gaspar, F. Bertucci et al., Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study, Eur J Cancer, vol.119, pp.151-157, 2019.

Y. Li, D. Wang, and X. Fang, In vitro generation of anti-osteosarcoma cytotoxic activity using dendritic cells loaded with heat shock protein 70-peptide complexes, Fetal Pediatr Pathol. 1-12, 2019.

Z. Li, H. Peng, Q. Xu, and Z. Ye, Sensitization of human osteosarcoma cells to Vg9d2 T cell mediated cytotoxicity by zoledronate, J Orthop Res, vol.30, issue.5, pp.824-854, 2012.

C. Lin, S. Mak, P. A. Meitner, J. M. Wolf, E. M. Bluman et al., , 2002.

, Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma, Gene, vol.285, issue.1-2, pp.269-78

W. Lin, D. Xu, C. D. Austin, P. Caplazi, K. Senger et al., Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer, 2019.

, , vol.10, 2019.

M. Lipinski, K. Braham, I. Philip, J. Wiels, T. Philip et al., , 1987.

, Neuroectoderm-associated antigens on Ewing's sarcoma cell lines, Cancer Res, vol.47, issue.1, pp.183-187

M. Liu, L. L. Sun, Y. J. Li, H. Y. Li, J. Zhang et al., Trastuzumab enhanced the cytotoxicity of V?9V?2 T cells against zoledronate-sensitized osteosarcoma cells, Int Immunopharmacol, vol.28, issue.1, pp.160-167, 2015.

S. Lorenz, T. Barøy, J. Sun, T. Nome, D. Vodák et al., Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations, Oncotarget, vol.7, issue.5, pp.5273-88, 2016.

Y. J. Lu, H. Chu, L. W. Wheeler, M. Nelson, E. Westrick et al., , 2019.

, Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies. Front Oncol, vol.9, p.151

D. M. Lussier, J. L. Johnson, P. Hingorani, and J. N. Blattman, Combination immunotherapy with ?-CTLA-4 and ?-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma, J Immunother Cancer, vol.3, p.21, 2015.

I. Machado, J. A. Lopez-guerrero, K. Scotlandi, P. Picci, and A. Llombart-bosch, , 2018.

, Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT), Virchows Arch, vol.472, issue.5, pp.815-824

M. B. Madel, L. Ibáñez, A. Wakkach, T. J. De-vries, A. Teti et al., Immune function and diversity of osteoclasts in normal and pathological conditions. Front Immunol, vol.10, p.1408, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02402778

N. Marina-garcia, L. Franchi, Y. G. Kim, D. Miller, C. Mcdonald et al., Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2, J Immunol, vol.180, issue.6, pp.4050-4057, 2008.

R. G. Majzner, J. S. Simon, and J. F. Grosso, Assessment of programmed deathligand 1 expression and tumor-associated immune cells in pediatric cancer tissues, Cancer, vol.123, issue.19, pp.3807-3815, 2017.

R. G. Majzner, J. L. Theruvath, A. Nellan, S. Heitzeneder, Y. Cui et al.,

, CAR T cells targeting B7-H3, a pan cancer antigen, demonstrate potent preclincial activity against pediatric solid tumors and brain tumors, Clin Cancer Res, vol.25, issue.8, pp.2560-2574

N. Martinez-velez, E. Xipell, P. Jauregui, M. Zalacain, L. Marrodan et al., The oncolytic adenovirus ?24-RGD in combination with cisplatin exerts a potent antiosteosarcoma activity, J Bone Miner Res, vol.29, issue.10, pp.2287-2296, 2014.

T. A. Mceachron, T. J. Triche, L. Sorenson, D. M. Parham, and J. D. Carpten, Profiling targetable immune checkoints in osteosarcoma, Oncoimmunology, vol.7, issue.12, p.1475873, 2018.

P. A. Meyers, C. L. Schwartz, and M. D. Krailo, Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group, J Clin Oncol, vol.26, pp.633-638, 2008.

S. Miwa, H. Nishida, Y. Tanzawa, A. Takeuchi, and K. Hayashi, Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma, Cancer, vol.123, issue.9, pp.1576-1584, 2017.

S. Miwa, T. Shirai, N. Yamamoto, K. Hayashi, A. Takeuchi et al., Current and emerging targets in immunotherapy for osteosarcoma, J Oncol, p.7035045, 2019.

K. Mori, K. Ando, and D. Heymann, Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Rev Anticancer Ther, vol.8, pp.151-159, 2008.

K. Mori, F. Rédini, F. Gouin, B. Cherrier, and D. Heymann, Osteosarcoma : current status of immunotherapy and future trends, Oncol Rep, vol.15, issue.3, pp.693-700, 2006.
URL : https://hal.archives-ouvertes.fr/inserm-00667509

J. J. Morrow, I. Bayles, A. P. Funnell, T. E. Miller, A. Saiakhova et al., Positively selected enhancer elements endow osteosarcoma cells with metastatic competence, Nat Med, vol.24, issue.2, pp.176-185, 2018.

M. Muraro, O. M. Mereuta, F. Carraro, E. Madon, and F. Fagioli, Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells, Cell Immunol, vol.249, issue.2, pp.63-72, 2007.

M. Muthana, S. Rodrigues, Y. Y. Chen, A. Welford, R. Hughes et al.,

, Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation, Cancer Res, vol.73, issue.2, pp.490-495

A. Nardin, M. L. Lefbvre, K. Labroquère, O. Faure, and J. P. Abastado, Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma, Curr Cancer Drug Targets, vol.6, issue.2, pp.123-156, 2006.

R. Noy and J. W. Pollard, Tumor-associated macrophages: from mechanisms to therapy, Immunity, vol.41, pp.49-61, 2014.

J. H. Pahl, K. M. Kwappenberg, E. M. Varypataki, S. J. Santos, M. L. Kuijjer et al., Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon, J Exp Clin Cancer Res, vol.33, p.27, 2014.

E. Palmerini, C. Agostinelli, P. Picci, S. Pileri, T. Marafioti et al., , 2017.

, PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1, Tumoral immune-infiltrate (IF), vol.8, pp.111836-111846

Y. Pignochino, F. Capozzi, L. D'ambrosio, C. Dell'aglio, M. Basirico et al., PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models, Mol Cancer, vol.16, issue.1, p.86, 2017.

S. M. Pollack, Y. Li, M. J. Blaisdell, E. A. Farrar, J. Chou et al., , 2012.

, NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine, PLoS One, vol.7, issue.2, p.32165

G. Polychronidou, V. Karavasilis, S. M. Pollack, P. H. Huang, A. Lee et al., Novel therapeutic approaches in chondrosarcoma, Future Oncol, vol.13, issue.7, pp.637-648, 2017.

C. Ratti, L. Botti, V. Cancila, S. Galvan, I. Torselli et al., Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors, Clin Cancer Res, vol.23, issue.17, pp.5149-5161, 2017.

M. C. Scott, N. A. Temiz, A. E. Sarver, R. S. Larue, S. K. Rathe et al., , 2018.

, Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma, Cancer Res, vol.78, issue.2, pp.326-337

F. A. Schildberg, S. R. Klein, G. J. Freeman, and A. H. Sharpe, Coinhibitory pathways in the B7-CD28 ligand-receptor family, Immunity, vol.44, issue.5, pp.955-72, 2016.

A. I. Ségaliny, A. Mohamadi, B. Dizier, A. Lokajczyk, R. Brion et al., Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma trhough induction of angiogenesis and macrophage recruitment, Int J Cancer, vol.137, pp.73-85

T. Shimizu, Y. Fuchimoto, H. Okita, K. Fukuda, Y. Kitagawa et al., A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: An in vivo study using a murine model of osteosarcoma, J Pediatr Surg, vol.53, issue.12, pp.2460-2464, 2018.

B. Silva-santos, K. Serre, and H. Norell, ?? T cells in cancer, Nat Rev Immunol, vol.15, issue.11, pp.683-91, 2015.

F. A. Simard, I. Richert, . A. Vandermoeten, A. V. Decouvelaere, J. P. Michot et al., Description of the immune microenvironment of chondrosarcoma and contribution to progression, Oncoimmunology, vol.6, issue.2, p.1265716, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01795707

C. Spurny, S. Kailayangiri, S. Jamitzky, B. Altvater, E. Wardelmann et al., Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas, Pediatr Blood Cancer, vol.65, issue.1, 2018.

Y. T. Sundara, M. Kostine, A. H. Cleven, J. V. Bovée, M. W. Schilham et al., Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy, Cancer Immunol Immunother, vol.66, issue.1, pp.119-128, 2017.

P. Tan, C. Zou, B. Yong, J. Han, L. Zhang et al., Expression and prognostic relevance of PRAME in primary osteosarcoma, Biochem Biophys Res Commun, vol.419, issue.4, pp.801-808, 2012.

M. Tellez-gabriel, M. F. Heymann, and D. Heymann, Circulating tumor cells as a tool for assessing tumor heterogeneity, Theranostics, vol.9, issue.16, pp.4580-4594, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02110266

P. Thanindratarn, D. C. Dean, S. D. Nelson, F. J. Hornicek, and Z. Duan, Advances in immune checkpoint inhibitors for bone sarcoma therapy, J Bone Oncol, vol.15, p.100221, 2019.

S. Théoleyre, K. Mori, B. Cherrier, N. Passuti, F. Gouin et al., , 2005.

, Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma, BMC Cancer, vol.5, p.123

N. Tsuda, K. Murayama, H. Ishida, K. Matsunaga, S. Komiya et al., Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides, J Orthop Res, vol.19, issue.3, pp.346-351, 2001.

H. A. Twabi, M. Burgess, V. Bolejack, B. A. Van-tine, S. M. Schuetze et al., Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial, Lancet Oncol, vol.18, issue.11, pp.30624-30625, 2017.

A. E. Van-erp, Y. M. Versleijen-jonkers, M. H. Hillebrandt-roeffen, L. Van-houdt, M. A. Gorris et al., Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8 + lymphocytes in primary sarcomas is subtype dependent, Oncotarget, vol.8, issue.41, pp.71371-71384, 2017.

S. Wang, H. Li, C. Ye, P. Lin, B. Li et al., Valproic acid combined with zoledronate enhance ?? T cell-mediated cytotoxicity against osteosarcoma cells via the accumulation of mevalonate pathway intermediates, p.377, 2018.

L. Wang, Q. Zhang, W. Chen, B. Shan, Y. Ding et al., B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis, PLoS One, vol.8, issue.8, p.70689, 2013.

Y. Wang, W. Yu, J. Zhu, J. Wang, K. Xia et al., Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma, J Exp Clin Cancer Res, vol.38, issue.1, p.168, 2019.

Z. Wang, Z. Wang, S. Li, B. Li, L. Sun et al., Decitabine Enhances V?9V?2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis. Front Immunol, vol.9, p.1239, 2018.

J. S. Whelan, L. E. Davis, C. Osteosarcoma, and C. , J Clin Oncol, vol.10, issue.2, pp.188-193, 2018.

S. S. Withers, D. York, J. W. Choi, K. D. Woolard, R. Laufer-amorim et al., Metastatic immune infiltrates correlate with those of the primary tumor in canine osteosarcoma, Vet Comp Oncol, vol.17, issue.3, pp.242-252, 2019.

L. Xia, H. Wu, and W. Qian, Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma, J Bone Oncol, vol.12, pp.61-64, 2018.

X. Yang, G. Zhu, Z. Yang, K. Zeng, F. Liu et al., Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma, Int J Biol Markers, vol.1724600818774464, 2018.

S. J. Yin, W. J. Wang, and J. Y. Zhang, Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice, Genet Mol Res, vol.14, issue.4, pp.14253-61, 2015.

A. J. Zendman, A. A. Van-kraats, U. H. Weidle, D. J. Ruiter, and G. N. Van-muijen, The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma, Int J Cancer, vol.99, issue.3, pp.361-369, 2002.

B. Zheng, T. Ren, Y. Huang, K. Sun, S. Wang et al., PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse, Hematol Oncol, vol.11, issue.1, p.16, 2018.

B. Zheng, T. Ren, Y. Huang, K. Sun, S. Wang et al., PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse, J Hematol Oncol, vol.11, issue.1, p.16, 2018.

Q. Zhou, M. Xian, S. Xiang, D. Xiang, X. Shao et al., All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages, Cancer Immunol Res, vol.5, pp.547-559, 2017.

C. Zou, J. Shen, Q. Tang, Z. Yang, J. Yin et al., Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis, Cancer, vol.118, issue.7, pp.1845-1855, 2012.